CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene® molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
Help employers find you! Check out all the jobs and post your resume.
